21
May

In this week’s EuroBiotech Report, Abivax became the latest French biotech to file for an IPO in its home country, seeking cash ahead of moving an HIV drug into two Phase IIb trials, as well as to support the clinical development of its lead candidate, a therapeutic vaccine against hepatitis B. And more.

…read more

Source: Abivax files for IPO, Pluristem boards EMA fast-track, Ablynx inks Genzyme MS deal

    

0 No comments